Introduction
Malassezia pachydermatis is a non-lipophilic, nonmycelial, unipolar budding yeast characterized by a thick cell wall [1] . This yeast is a commensal on animal skin, but may become pathogenic under the infl uence of predisposing factors [2 -5] , leading to cases of otitis externa and different clinical forms of dermatitis in domestic animals of the chitin synthase-2 ( chs -2) gene, the fi rst internal transcribed spacer (ITS-1) and the large subunit (LSU) of nuclear rDNA has led to the categorization of M. pachydermatis isolated dogs into three major genotypes (i.e., A, B and C) [15, 16] . However, to date, no information is available on the in vitro susceptibility of M. pachydermatis genetic subpopulations to antifungal agents .
Since the number of human and animal reported skin infections by Malassezia is increasing rapidly [1, 5] , there is a need for in vitro susceptibility testing of this yeast to antifungal compounds. In 2002, the Clinical and Laboratory Standards Institute (CLSI; formerly the National Committee for Clinical Laboratory Standards [NCCLS] ) developed a reference method for such testing of Candida spp. and Cryptococcus neoformans [17] . This was subsequently adapted to Malassezia yeasts by modifying the media, time of incubation and inocula [13, 14, 18, 19] . The susceptibility of Malassezia to antifungal compounds has also been tested using alternative methods, such as the disk diffusion [20 -22] and the E-test stable gradient, with controversial results [18, 23, 24] .
The aims of this study were: (i) to evaluate the antifungal susceptibility of M. pachydermatis strains recovered from dogs with and without skin lesions to KTZ, fl uconazole (FLZ), ITZ, posaconazole (POS) and voriconazole (VOR) using both the CLSI broth microdilution (BMD) and the E-test; (ii) to estimate the agreement of results obtained with the E-test and CLSI BMD methods; and (iii) to test the hypothesis of an association between in vitro susceptibility of M. pachydermatis to antifungal compounds and the yeast ' s genetic subpopulations .
Materials and methods

Malassezia isolates and their phenotypic identifi cation
Malassezia pachydermatis isolates ( n ϭ 62) were collected from 62 dogs with or without skin lesions and/or otitis which comprised two groups, i.e., Group A included 30 isolates from 30 dogs in good general health with no history of skin or ear diseases and that had not been treated in the preceding fi ve months and Group B consisting of 32 isolates from 32 dogs with cutaneous lesions. In the latter group were fi ve dogs that had localized dermatitis characterized by erythema and pruritus at only one site (i.e., two dogs with otitis and pinna hyperkeratosis and three with inguinal dermatitis) and the remaining 27 animals had generalized lesions characterized by pruritus, erythema, alopecia, excoriations, seborrhoea, lichenifi cation and ⁄ or hyperpigmentation.
Samples were collected from each animal by rubbing sterile swabs on seven different anatomical areas (i.e., left and right ear canals, ventral neck, left and right axilla, and left and right groin). After collection, samples were inoculated onto modifi ed Dixon Agar (mDA) and incubated at 32 ° C for 10 days. Malassezia pachydermatis isolates were identifi ed phenotypically based on their macroscopic and microscopic morphology and their ability to grow on media without lipid supplementation (Sabouraud Dextrose Agar, Biolife-SAB) [25] . Additional tests were conducted which included assessment of assimilation of different Tweens (i.e., Tweens 20, 40, 60, 80; Italy) and cremophor EL (PeG 35 castor oil, Sigma-Aldrich, Italy), pigment production on tryptophan-based medium and growth on mDA at 32 and 40 ° C. Isolates were maintained on mDA until molecular characterization and testing of in vitro antifungal susceptibility. Isolates were deposited in the fungal collection of the Faculty of Veterinary Medicine at the University of Bari, Italy.
PCR amplifi cation and multilocus sequencing for Malassezia genotyping
Genomic DNA was extracted from 1 ml culture (containing ∼ 1 -2 ϫ 10 8 cells) of each isolate, as described previously [15, 16] . The chs-2 gene ( ∼ 540 bp) was amplifi ed from genomic DNA by the polymerase chain reaction (PCR) using the primers CED1 and CED2, the ITS-1 region ( ∼ 282 bp) using the primers 18SF1 and 5.8SR1 and the D1/D2 regions of the LSU rRNA gene ( ∼ 640 bp) using the primers F63 and LR3 [15, 16] . Genomic DNA (4 μ l) was added to the PCR mix (46 μ l) containing 2.5 mM MgCl 2 , 10 mM Tris-HCl, pH 8.3 and 50 mM KCl, 250 μ M of each dNTP, 50 pmol of each primer and 1.25 U of Ampli Taq Gold (Applied Biosystems, Milan, Italy). The PCR was performed in a thermal cycler (Gene Amp PCR System 2700, Applied Biosystems, Milan, Italy) at 94 ° C for 12 min (polymerase activation), followed by 25 -30 cycles of 94 ° C for 1 min ( chs-2) or 30 sec (LSU and ITS-1) (denaturation), respectively; 55 ° C (LSU) and 60 ° C for 1 min ( chs-2) or 15 sec (ITS-1) (annealing); 72 ° C for 2 min ( chs-2) or 1 min (LSU) or 15 sec (ITS-1) (extension), followed by 7 min at 72 ° C (fi nal extension). Amplicons were resolved in 2% w/v agarose (Gellyphor, Euroclon, Milan, Italy) gels, stained with ethidium bromide (10 mg/ml) and then purifi ed using Ultrafree-DA columns (Amicon, Millipore; Bedford, USA) and sequenced directly using the Taq DyeDeoxyTMTerminator Cycle Sequencing Kit (v.2, Applied Biosystems, Milan, Italy) employing an automated sequencer (ABI-PRISM ® 377; Applied Biosystems, Milan, Italy). Sequences were determined from both strands (using the same primers as used for the PCR) and the electropherograms were checked visually. Sequences were aligned using the program Clustal X [26] and compared with Malassezia sequences available in the GenBank TM database (http://www.ncbi.nlm.nih.gov).
than two-fold dilutions between the methods. Categorical agreement (CA) was assigned to susceptibility testing results falling within the same category of interpretation [32] .
The discrepancies between tests were classifi ed as: (i) ' minor ' , isolates classifi ed as S or R by one of the two tests, and as I by the other method; (ii) ' major ' , isolate classifi ed as S by the CLSI BMD and ' R ' by the E-test; and (iii) ' very major ' , isolate classifi ed as ' R ' by the CLSI BMD and ' S ' by the E-test [33] .
Statistical analysis
Agreement between the MICs determined by two different susceptibility-testing methods was assessed using Bland Altman test. In particular, the test was applied on log 2 transformed data.
KTZ, ITZ, VOR, POS and FLZ, CLSI BMD MIC values for genetic population of M. pachydermatis were screened by the one-way analysis of variance (ANOVA I).
MIC values of genotype A, B and C coming from animals with and without lesions were compared using Student ' s t -test and the homoscedasticity of variances was evaluated using the Fisher ' s test.
The χ 2 test was employed to compare the prevalence of M. pachydermatis strains with genotype A, B and C resulting susceptible (S), intermediary susceptible (I) and resistant (R) to the fungal drugs tested. Data were statistically analysed using R software (version 2.8.1). A P -value less than 0.05 was considered signifi cant.
Results
Fifty isolates were phenotypically identifi ed as not lipid dependent M. pachydermatis and 12 as lipid depended (LD) as previously reported [15] . In particular, all LD isolates were catalase positive, did not grow on Sabouraud agar but did grow on modifi ed Dixon agar (at 32, 37 and 40 ° C), assimilated Cremophor EL, Tween 20, 40, 60 and 80, did not hydrolyze esculin and did not consume tryptophan as a nitrogen source.
The PCR amplifi cation of the chs-2 gene, ITS-1 and LSU of nuclear rDNA from individual DNA samples of M. pachydermatis isolates resulted in amplicons of the expected sizes [15, 16] . Sequencing of amplicons revealed three sequence-types for chs-2 (namely A c , B c , C c ), and LSU (A L , B L , C L ) and four for ITS-1 (A I , B I , C 1I, C 3I ). All chs-2, LSU and ITS-1 sequence-types of M. pachydermatis matched previously determined sequences of isolates available in GenBank and DDJB databases (accession numbers: DQ915500 -DQ915509; EU158826, EU158827 and EU158829) [15, 16] . Genotypic grouping (A -C) was concordant between chs-2, LSU and ITS-1 [15,16] and three major M. pachydermatis genotypes were identifi ed,
In vitro susceptibility testing
The in vitro susceptibility of M. pachydermatis strains to antifungal compounds was assessed employing the reference CLSI M27-A2 method, using the Sabouraud dextrose medium (Liofi lchem Diagnostici, Roseto degli Abruzzi, Italy-SDB) with 1% of Tween 80 (Sigma Co, Milano, Italy) [14] . In particular, Sabouraud dextrose medium with 1% of Tween 80 was employed since M. pachydermatis genotype B grows better in this medium as it is lipid dependent [15] .
The E-test strips (AB BIODISK, Solna, Sweden) for KTZ, ITZ, VOR, POS (concentrations ranging from 0.002 -32 mg/l) and for FLZ (from 0.16 -256 mg/l) were used in the testing. Stock inoculum suspensions were prepared from 7-days-old M. pachydermatis colonies incubated on modifi ed Dixon agar at 32 ° C. The fi nal concentration of the stock inoculum suspensions in sterile distilled water was adjusted to an optical density of 2.4 using a turbidimeter (DEN-1 McFarland Densitometer, Biosan) which was equivalent to 1 -5 ϫ 10 6 colony forming unit (CFU)/ml, as validated by quantitative plate counts of CFU on Sabouraud Dextrose agar 1% of tween 80.
Sterile cotton swabs were dipped into the inoculum suspension and then streaked onto Sabouraud dextrose agar (SDA; Liofi lchem Diagnostici, Roseto degli Abruzzi, Italy) containing 1% of Tween 80 with E-test strips placed in the centre of the plate. The inoculated plates were incubated at 32 ° C and read after 48 h. The drug concentration shown on the E-test strip at the outer border of the elliptical inhibition halo was recorded as MIC. The growth of microcolonies within this inhibition zone was disregarded [27] and the MIC data reported as values at which 50% (MIC 50 ) and 90% (MIC 90 ) of isolates growth were inhibited.
Quality control strains ( C. parapsilosis ATCC 22019 and C. krusei ATCC 6258; American Type Culture Collection, Manassas, VA, USA) were included on each day to check the accuracy of the drug dilutions and the reproducibility of the results [28] .
Tentative breakpoints have been established for azole compounds, allowing isolates of Candida spp. tested in accord with CLSI guidelines to be classifi ed as susceptible, susceptible dose-dependent, or resistant [29] . However, since these breakpoints have not yet been established for M. pachydermatis , the following criteria were used in both tests to categorize M. pachydermatis isolates: susceptible (S) ϭ MIC sample Յ MIC 50 ; intermediary susceptible (I) ϭ MIC 50 Ͻ MIC sample Յ MIC 90 ; and resistant (R) ϭ MIC sample Ͼ MIC 90 [13, 14, 23, 24, 30, 31] . The categories (i.e., S, I, R) obtained with the E-test method were compared to those obtained using the CLSI BMD reference procedure. Essential agreement (EA) was defi ned as discrepancies in MIC results of no more i.e., A ( n ϭ 36), B ( n ϭ 12) and C ( n ϭ 14)]. All LD Malassezia pachydermatis belonged to Genotype B as previously reported [15] (Table 2) relative to the antifungal drugs tested. Concordance was high for ITZ (96.8%) and POS (91.9%). When discrepancies between the two methods were observed, the majority of them were registered as ' minor error ' (Table 2), whereas ' very major ' discrepancies were found for KTZ (Table 2 ). Fig. 1 (Table 3 ). In contrast, the MIC mean value of M. pachydermatis genotype A to KTZ was statistically higher in isolates from dogs without lesions than those from animals with skin lesions (Table 3) . A larger number of VOR and FLZ susceptible strains were noted among M. pachydermatis genotype A than among genotypes B and C ( P Ͻ 0.001, Table 4 ) whereas a larger number of FLZ intermediary susceptible strains were recorded among genotype B isolates compared with genotypes types A and C ( P Ͻ 0.001) ( Table 4) .
Discussion
The results from the present study provide valuable information on the susceptibility of M. pachydermatis isolates to antifungal compounds. ITZ, KTZ and POS showed the highest antifungal activity, using both methods, with an overall EA Ͼ 90% for all drugs tested except VOR (87.1%). Similarly, the recorded CA was Ͼ 80% for all drugs tested a Percentage of isolates classifi ed as susceptible (S); intermediary susceptible (I); and resistant (R). b Percentage of results representing minor (isolates classifi ed as ' S ' or ' R ' by one of the two tests), major (isolate classifi ed as ' S ' by the CLSI BMD and ' R ' by the E-test), or very major (isolate classifi ed as ' R ' by the CLSI BMD and ' S ' by the E-test) discrepancies with respect to those of the reference (CLSI M27-A2) method. CA refl ects the percentage of isolates classifi ed in the same category by the reference (CLSI M27-A2) method and E-test method.
except for KTZ (77.4%) and FLZ (74.2%). In particular, when discrepancies between the two methods were observed, they were minor errors, with only three very major errors found with KTZ. This fi nding is likely due to the limitations of the reference method employed [18] . Indeed, trailing endpoints, a well-described phenomenon with CLSI BMD method in tests with azoles, can lead to over interpretation of the MICs [18] . Furthermore, it has been proposed that, in order for a susceptibility test to be considered specifi c, less than 5% very major and major errors should occur [33] . Therefore, the results from our study show that the E-test method represents an alternative to test the susceptibility of M. pachydermatis to all azole compounds used in our studies, with the exception of KTZ.
To our knowledge, a limited number of studies have compared the E-test and CLSI BMD methods in in vitro antifungal susceptibility of Malassezia yeasts. Velegraki et al. [18] reported concordance between the E-test and CLSI BMD methods, whereas the results from studies by Nascente et al . [23, 24] emphasized the need for standardization of the tests. In particular, it has been suggested that the same media should be employed to achieve concordant microdilution and E-test results [18] . In this study, we used SDA medium with 1% of Tween 80, an inoculum suspension equivalent to 1 -5 ϫ 10 6 CFU/ml and 48-h incubation time, which revealed a very good agreement between the E-test and CLSI BMD methods in susceptibility tests of M. pachydermatis to different azole compounds. Additionally, the statistical analysis of the results shows that limits of agreement were small enough to confi rm that E-test method can be used in place of the CLSI BMD for clinical purpose [34] . In particular, the E-test method is simple to perform, does not require any specialized laboratory equipment and can be used for the routine testing of this species. In this study, an association of M. pachydermatis [15, 16] . The lipid dependence is usually associated with a defi ciency of genes encoding fatty acid synthase and to an abundance of genes encoding hydrolases, both of which might determine the lipid composition of cell wall [36] . Similarly, the different antifungal susceptibilities of M. pachydermatis genotype B found here might be linked to the fact that the composition of skin lipids differs in animals with lesions, thus affecting drug susceptibility. Indeed, resistance to antifungal compounds has been observed in cases of alteration of the composition of membrane sterol [37] and/or the up-regulation of CDR genes encoding the CDR effl ux pumps [38] .
In conclusion, the results of this study confi rm that M. pachydermatis is highly susceptible to ITZ and KTZ, while susceptibility to FLZ is limited. The data reported herein also provide evidence that posaconazole could be used in therapeutics of generalized M. pachydermatis infections. Finally, the good categorical agreement between the E-test and the reference CLSI broth microdilution method provides further confi rmation of the reliability of the former method for routine use in clinical mycology laboratories. Future studies should focus on testing the correlation between the susceptibility to antifungal agents in vitro and in vivo . 
